BASF/Knoll Faces Lawsuit In USA Over Synthroid
Alawsuit has been submitted on behalf of 8 million patients in the USAwho use Synthroid (levothyroxine), a treatment for hypothyroidism, against BASF and its US subsidiary Knoll Pharmaceutical. BASF gained the product in 1995 through its acquisition of the pharmaceutical business of the UK company Boots.
It is alleged that Boots, and then BASF and Knoll, concealed a study conducted nine years ago that concluded that Synthroid and another brand-name levothyroxine product were bioequivalent to two generic products (Marketletter April 28). BASF and Knoll finally agreed to the publication of the study in November last year.
Linda Mayer, Knoll's spokesperson in the USA, told the Marketletter that the company will defend itself vigorously, and that the charges are completely unfounded.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze